Reglagene’s mission is to discover and develop low-cost and noninvasive therapeutic solutions that reprogram genes exploited by cancer to keep patients responsive to treatment.
Pioneering the field
Reglagene’s technology is the product of 20 years of meticulous research from the labs of Professor Laurence Hurley at the University of Arizona. Professor Hurley discovered that unusual DNA structures called “quadruplexes,” found in many genes exploited by cancer and other diseases, are actually master controllers of gene expression.
Sensing an opportunity to use this discovery for the benefit of patients, Professor Hurley pioneered Quadruplex Master Switch Technology (QMST) to enable the development of medicines that fight disease through the control of gene expression.
In QMST's early days, finding both potent and selective medicines seemed impossible. In 2006 Professor Hurley dedicated his research to solving this problem. Since 2014 he has released a flurry of papers describing new quadraplex applications against many of the most important targets in cancer and other diseases. This latest research is the basis for the founding of Reglagene.
Reglagene is applying QMST to the development of Epigenetic Medicines. These are orally administered medicines that target abnormal genes and regulate their expression. Through regulating abnormal genes, Reglagene will facilitate abatement of life-threatening diseases such as prostate cancer and glioblastoma.